STXS

Stereotaxis, Inc. STXS

NYSESmall CapHealthcare

13F Pro quality score

Rank #2,689 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$7.67M

Quarter to Jun 30

Net income

$-4.47M

Quarter to Jun 30

Free cash flow

$-3.74M

Quarter to Jun 30

Operating margin

-59.6%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$69.11M total
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/STXS

Earnings Per Share

13fpro.ai/company/STXS

Loading ratio trend…

STXS key financials by period

Reported revenue, net income and operating margin by fiscal year, from Stereotaxis, Inc.'s annual filings on SEC EDGAR.

Stereotaxis, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$32.4M$-21.6M-68.3%
FY 2024$26.9M$-24.0M-91.9%
FY 2023$26.8M$-20.7M-81.6%
FY 2022$28.1M$-18.3M-66.7%
FY 2021$35.0M$-10.7M-36.8%
FY 2020$26.6M$-6.6M-25.2%
Source: STXS filings on SEC EDGAR →

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

STXS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Stereotaxis, Inc. (STXS): stock profile, AI score and financials

Stereotaxis, Inc. (STXS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STXS at 23.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,689 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (4.1) and revenue scale (5.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Stereotaxis, Inc. reports quarterly revenue of $7.7M, net income of $-4.5M, an operating margin of -59.6%. Top institutional holders of STXS by reported 13-F value include DAFNA Capital Management, BlackRock, Lagoda Investment Management, L.P., based on the most recent SEC filings. STXS trades on the NYSE exchange and files with the SEC under CIK 1289340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STXS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Stereotaxis, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1289340 →